Spiller H A, Villalobos D, Krenzelok E P, Anderson B D, Gorman S E, Rose S R, Fenn J, Anderson D L, Muir S J, Rodgers G C
Kentucky Regional Poison Center, Louisville 40232-5070, USA.
J Pediatr. 1997 Jul;131(1 Pt 1):141-6. doi: 10.1016/s0022-3476(97)70138-0.
Sixty-eight percent of pediatric sulfonylurea ingestions reported to poison centers do not result in laboratory or behavioral effects. Consequently, if all exposed children are admitted overnight or for 24 hours for these exposures, it will result in 600 to 700 hospital admissions per year of children who will remain free of symptoms. We prospectively studied exposures reported to 10 regional poison centers to determine if it were possible to differentiate those patients who would have symptoms from those who would remain symptom free.
We analyzed all sulfonylurea exposures in children < or = 12 years old reported to the participating poison centers. Hypoglycemia was defined as blood glucose (BG) concentration < 60 mg/dl.
Hypoglycemia developed in 56 (30%) of 185 exposed patients. Fifty-four of the 56 (96%) hypoglycemic patients had development of hypoglycemia within 8 hours of ingestion. Eighty-seven of the patients were initially managed with oral supplementation only; in 13 cases, treatment advanced to intravenous administration of glucose or glucagon with the onset of hypoglycemia. There was no statistical difference in medical outcome between patients monitored during oral supplementation versus during intravenous infusion of dextrose. Ingestions analyzed by time of day did not predict risk of hypoglycemia. Sufficient data were available for 103 (58%) of the 177 patients who ingested glyburide or glipizide to calculate a toxic dose/weight ratio. Of these 103 patients, 31 of 36 patients who ingested < or = 0.3 mg/kg remained symptom free, whereas 31 of 67 who ingested more than 0.3 mg/kg had BG concentrations < 60 mg/dl (p < 0.005, 95% confidence interval 0.05 to 0.58; sensitivity 86%, specificity 46%).
A lack of onset of hypoglycemia (BG > 60 mg/dl) in the first 8 hours after ingestion is predictive of a benign outcome in accidental pediatric sulfonylurea ingestion. Clinical observation of children for onset of hypoglycemia during oral feeding alone appears safe. Some children with symptoms of hypoglycemia need to receive intravenous dextrose therapy. Time of day of ingestion is not predictive of risk of hypoglycemia. Finally, at this time it appears inappropriate to use a milligram per kilogram body weight dose as a guide for management decisions.
向中毒控制中心报告的儿童磺脲类药物摄入事件中,68%未导致实验室检查异常或出现行为影响。因此,如果所有暴露儿童因这些暴露事件住院过夜或24小时,每年将有600至700名儿童住院,而这些儿童不会出现症状。我们对向10个地区中毒控制中心报告的暴露事件进行了前瞻性研究,以确定是否有可能区分哪些患者会出现症状,哪些患者将无症状。
我们分析了向参与研究的中毒控制中心报告的所有12岁及以下儿童的磺脲类药物暴露事件。低血糖定义为血糖(BG)浓度<60mg/dl。
185名暴露患者中有56名(30%)出现低血糖。56名低血糖患者中有54名(96%)在摄入后8小时内出现低血糖。87名患者最初仅接受口服补充治疗;13例患者在出现低血糖时治疗进展为静脉输注葡萄糖或胰高血糖素。口服补充治疗期间监测的患者与静脉输注葡萄糖期间监测的患者在医疗结局方面无统计学差异。按一天中的时间分析摄入情况并不能预测低血糖风险。177名服用格列本脲或格列吡嗪的患者中有103名(58%)有足够的数据来计算中毒剂量/体重比。在这103名患者中,摄入≤0.3mg/kg的36名患者中有31名无症状,而摄入超过0.3mg/kg的67名患者中有31名BG浓度<60mg/dl(p<0.005,95%置信区间0.05至0.58;敏感性86%,特异性46%)。
摄入后最初8小时内未出现低血糖(BG>60mg/dl)可预测儿童意外磺脲类药物摄入的良性结局。仅在口服喂养期间对儿童进行低血糖发作的临床观察似乎是安全的。一些有低血糖症状的儿童需要接受静脉葡萄糖治疗。摄入时间不能预测低血糖风险。最后,目前将每公斤体重毫克剂量用作管理决策指南似乎不合适。